Abstract

Moderate doses of lithium were chronically administered to mice in order to verify whether the cytoprotective effects of lithium could be in part attributed to a molecular protection conferred by stress proteins/chaperones accumulation. In order to reach serum lithium levels within the common therapeutic values, mice were fed for 6months on food pellets contained 1g (L1 group) or 2g (L2 group) lithium carbonate/kg, resulting in serum concentrations of 0.5 and 0.9mM Li, respectively. Under these experimental conditions, no clinical side-effects were observed. Urea and creatinine concentrations in serum, lipids peroxidation level and activities of catalase, superoxide-dismutase and glutathione-peroxidase in liver and kidney were not significantly different from control values. Although the expression level of the constitutive HSP73 was not significantly modified, HSP72 was found to be down-regulated in kidney after 1month. In liver, three protein bands were immunodetected by the anti-GRP94 antibody: 98kDa and 96kDa proteins corresponding to more or less glycosylated forms and/or phosphorylated forms of GRP94 and a 80kDa protein probably being a cleavage product of GRP94. The 96kDa and 80kDa proteins were significantly up-regulated in liver of lithium-treated mice as compared to controls.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call